Back to Search
Start Over
How the Xenopus eleutheroembryonic thyroid assay compares to the amphibian metamorphosis assay for detecting thyroid active chemicals.
- Source :
-
Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2024 May; Vol. 149, pp. 105619. Date of Electronic Publication: 2024 Apr 13. - Publication Year :
- 2024
-
Abstract
- The Xenopus Eleutheroembryonic Thyroid Assay (XETA) was recently published as an OECD Test Guideline for detecting chemicals acting on the thyroid axis. However, the OECD validation did not cover all mechanisms that can potentially be detected by the XETA. This study was therefore initiated to investigate and consolidate the applicability domain of the XETA regarding the following mechanisms: thyroid hormone receptor (THR) agonism, sodium-iodide symporter (NIS) inhibition, thyroperoxidase (TPO) inhibition, deiodinase (DIO) inhibition, glucocorticoid receptor (GR) agonism, and uridine 5'-diphospho-glucuronosyltransferase (UDPGT) induction. In total, 22 chemicals identified as thyroid-active or -inactive in Amphibian Metamorphosis Assays (AMAs) were tested using the XETA OECD Test Guideline. The comparison showed that both assays are highly concordant in identifying chemicals with mechanisms of action related to THR agonism, DIO inhibition, and GR agonism. They also consistently identified the UDPGT inducers as thyroid inactive. NIS inhibition, investigated using sodium perchlorate, was not detected in the XETA. TPO inhibition requires further mechanistic investigations as the reference chemicals tested resulted in opposing response directions in the XETA and AMA. This study contributes refining the applicability domain of the XETA, thereby helping to clarify the conditions where it can be used as an ethical alternative to the AMA.<br />Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: David Du Pasquier, Benoit Salinier, Gregory Lemkine, Barbara Robin-Duchesne reports financial support was provided by CropLife Europe. Laurent Lagadic reports a relationship with Bayer CropScience AG that includes: employment. This work was supported by CropLife Europe as a Company Investment Project and research and development funds from Corteva Agriscience USA. The employment affiliation of the authors is listed on the cover page. BRD, BS, DDP and GL are affiliated to Laboratoire WatchFrog, developer of the Xenopus Eleutheroembryonic Thyroid Assay (XETA) and coordinator of the validation of OECD TG 248. AJ, JL, JRW, KKC, LL, LW and OK are affiliated to companies that manufacture agrochemicals, some of which having been used in the present study. There are no other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1096-0295
- Volume :
- 149
- Database :
- MEDLINE
- Journal :
- Regulatory toxicology and pharmacology : RTP
- Publication Type :
- Academic Journal
- Accession number :
- 38614220
- Full Text :
- https://doi.org/10.1016/j.yrtph.2024.105619